News | EP Lab | August 03, 2021

Spinal Cord Stimulation Helps Suppress AF in CABG Patients

HRS 2021 late-breaker shows another method to reduce atrial fibrillation in coronary bypass patients

emporary Spinal cord stimulation (SCS) was effective in suppressing post-operative atrial fibrillation (AF) after coronary artery bypass (CAGB) surgery CABG without any adverse events in a randomized pilot study. The TEmporary Spinal CoRd StiMulatIon to PrevenNt Atrial FibrillaTION AFter Cardiac Surgery (TerminationAF) study was presented as a late-breaking study presented at the 2021 Heart Rhythm meeting, the annual conference of the Heart Rhythm Society (HRS).  #HRS21 #HRS2021

August 4, 2021 — Temporary Spinal cord stimulation (SCS) was effective in suppressing post-operative atrial fibrillation (AF) after coronary artery bypass (CAGB) surgery CABG without any adverse events in a randomized pilot study. The TEmporary Spinal CoRd StiMulatIon to PrevenNt Atrial FibrillaTION AFter Cardiac Surgery (TerminationAF) study was presented as a late-breaking study presented at the 2021 Heart Rhythm meeting, the annual conference of the Heart Rhythm Society (HRS)

Spinal cord stimulation has been shown to be effective in the treatment of chronic pain and intractable angina pectoris. Recently, animal studies have demonstrated that SCS can also suppress AF, explained presenter Alexander B. Romanov, M.D., Ph.D., FHRS, E. Meshalkin National Medical Research Center of the Ministry of Health, Novosibirsk, Russia. He said this study looked at its application in human patients who underwent CABG to see if it could suppress AF in this patient population.

The study included 52 patients with indications for coronary artery bypass grafting (CABG) and history of paroxysmal AF were randomized to 2 groups: CABG plus standard medical therapy (MED) with beta-blockers (n=26, Control group) and CABG plus MED plus percutaneous lead placement for temporary SCS (n=26, SCS group). In the SCS group under local anesthesia and with fluoroscopic guidance, temporary leads were placed at C7-T4 level according to patient’s sense of paresthesia and connected to a SC stimulator externally fixed on patient’s chest. Temporary SCS was begun 3 days before elective CABG, deactivated during surgery, reactivated in the intensive care unit after CABG, and continued for 7 days at which time the leads were removed Continuous external ECG monitoring was performed for 30 days after CABG in all patients. These primary objectives were tested over the 30-day post-operative period: 1) occurrence of adverse events, including death, stroke or TIA, myocardial infarction and kidney injury; and 2) occurrence of AF or any atrial tachyarrhythmia lasting ≥ 30 seconds.

Percutaneous lead placement for temporary SCS was successfully performed in all 26 patients before CABG without any complications. There were no any adverse events related to temporary SCS in any patient throughout follow-up. There were no significant differences in CK-MB and creatinine levels between groups (p=0.1 and 0.2, respectively) as well as other typical CABG-related complications (p>0.05). Post-operative AF occurred in 8 (30.7%) of
26 patients in the Control group versus only 1 (3.8%) of 26 patients in the SCS group (p=0.012, log-rank test, Figure).

Researchers said further studies of SCS with larger samples should be conducted to test its clinical value as a peri-operative intervention.

Find additional HRS 2021 late breaking trials

Find more EP device news

Find more HRS 2021 conference news

 

Related Content

Feature | Atrial Fibrillation

Improved short-term monitoring methods for patients with stroke risk can increase early detection of atrial fibrillation ...

Home December 07, 2021
Home
News | Atrial Fibrillation

November 17, 2021 — People with atrial fibrillation (AFib) who underwent individualized testing to discover triggers for ...

Home November 17, 2021
Home
News | Atrial Fibrillation

September 28, 2021 — Image-guided fibrosis ablation in addition to pulmonary vein isolation (PVI) does not improve ...

Home September 28, 2021
Home
News | Atrial Fibrillation

September 13, 2021 — Ablation plus cardiac resynchronization therapy (CRT) is superior to pharmacological rate control ...

Home September 13, 2021
Home
News | Atrial Fibrillation

September 8, 2021 — Continuous heart rhythm monitoring – with anticoagulation if atrial fibrillation is detected – does ...

Home September 08, 2021
Home
News | Atrial Fibrillation

August 9, 2021 — Adagio Medical Inc., a provider of catheter ablation technologies for atrial fibrillation (AF) and ...

Home August 09, 2021
Home
News | Atrial Fibrillation

June 23, 2021 — The U.S. Food and Drug Administration (FDA) expanded approval for Medtronic's Arctic Front Family of ...

Home June 23, 2021
Home
News | Atrial Fibrillation

April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm ...

Home April 19, 2021
Home
News | Atrial Fibrillation

March 3, 2021 — Farapulse Inc. announced the first patients were treated in the ADVENT Trial, a U.S. Food and Drug ...

Home March 03, 2021
Home
News | Atrial Fibrillation

January 29, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Medtronic's DiamondTemp Ablation (DTA) system ...

Home January 29, 2021
Home
Subscribe Now